Orca Bio raised $250 million in financing to support the commercial launch of its T‑cell therapy for complications arising after allogeneic stem cell transplant. The round is intended to fund manufacturing scale‑up, market entry and rollout efforts for the company’s lead therapy targeting post‑transplant complications. Orca said the capital will shore up commercialization readiness and supply chain scale needed for cell therapy delivery at regional treatment centers. The financing highlights investor appetite for companies positioned to move cell therapies from clinical development into routine clinical use, particularly when a defined patient population and commercial pathway exist.